Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVGH Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Adults in Africa
NCT07663032Phase 1Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Pan-Salmonella vaccine in salmonellosis (5 arms), sponsored by GSK. Primary endpoints: Number of participants with solicited administration site events, Number of participants with solicited systemic events and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
Pan-Salmonella vaccine
03
Conditions
salmonellosis
Beyond the preview
Go deeper on NCT07663032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663032.